CY1114426T1 - Microrna (mirna) mir-21 για διαγνωστικους και θεραπευτικους σκοπους - Google Patents
Microrna (mirna) mir-21 για διαγνωστικους και θεραπευτικους σκοπουςInfo
- Publication number
- CY1114426T1 CY1114426T1 CY20131100690T CY131100690T CY1114426T1 CY 1114426 T1 CY1114426 T1 CY 1114426T1 CY 20131100690 T CY20131100690 T CY 20131100690T CY 131100690 T CY131100690 T CY 131100690T CY 1114426 T1 CY1114426 T1 CY 1114426T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fibrosis
- mir
- treatment
- prevention
- microrna
- Prior art date
Links
- 108091070501 miRNA Proteins 0.000 title abstract 3
- 108091008065 MIR21 Proteins 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 9
- 230000004761 fibrosis Effects 0.000 abstract 9
- 108091062762 miR-21 stem-loop Proteins 0.000 abstract 5
- 108091041631 miR-21-1 stem-loop Proteins 0.000 abstract 5
- 108091044442 miR-21-2 stem-loop Proteins 0.000 abstract 5
- 230000002265 prevention Effects 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000002679 microRNA Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 abstract 2
- 108700011259 MicroRNAs Proteins 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3183508P | 2008-02-27 | 2008-02-27 | |
| EP20080003570 EP2096171A1 (en) | 2008-02-27 | 2008-02-27 | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| US3334008P | 2008-03-03 | 2008-03-03 | |
| EP09714079.2A EP2260101B1 (en) | 2008-02-27 | 2009-02-26 | Microrna (mirna) mir-21 for diagnostic and therapeutic purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114426T1 true CY1114426T1 (el) | 2016-08-31 |
Family
ID=39639202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100690T CY1114426T1 (el) | 2008-02-27 | 2013-08-13 | Microrna (mirna) mir-21 για διαγνωστικους και θεραπευτικους σκοπους |
Country Status (23)
| Country | Link |
|---|---|
| US (10) | US8236777B2 (enExample) |
| EP (3) | EP2096171A1 (enExample) |
| JP (2) | JP6033527B2 (enExample) |
| KR (1) | KR101697482B1 (enExample) |
| CN (1) | CN102027113B (enExample) |
| AU (1) | AU2009218704C1 (enExample) |
| BR (1) | BRPI0907565B1 (enExample) |
| CA (2) | CA3123067A1 (enExample) |
| CY (1) | CY1114426T1 (enExample) |
| DK (1) | DK2260101T3 (enExample) |
| EA (1) | EA020335B1 (enExample) |
| ES (1) | ES2436885T3 (enExample) |
| HR (1) | HRP20130766T1 (enExample) |
| IL (1) | IL207704A (enExample) |
| ME (1) | ME01600B (enExample) |
| MX (2) | MX2010009346A (enExample) |
| MY (1) | MY159454A (enExample) |
| NZ (1) | NZ588185A (enExample) |
| PL (1) | PL2260101T3 (enExample) |
| PT (1) | PT2260101E (enExample) |
| SI (1) | SI2260101T1 (enExample) |
| UA (1) | UA100727C2 (enExample) |
| WO (2) | WO2009106477A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| WO2011017697A1 (en) * | 2009-08-07 | 2011-02-10 | New York University | Compositions and methods for treating inflammatory disorders |
| CN102038959B (zh) * | 2009-10-26 | 2012-12-19 | 中国科学院上海生命科学研究院 | let-7/miR-98家族在制备治疗FAS基因相关疾病的药物中的应用 |
| WO2011126842A2 (en) * | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
| US20130150256A1 (en) | 2010-06-11 | 2013-06-13 | Jane Synnergren | Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types |
| WO2012012716A2 (en) | 2010-07-23 | 2012-01-26 | Regulus Therapeutics, Inc. | Targeting micrornas for the treatment of fibrosis |
| EP2652151A2 (en) * | 2010-12-15 | 2013-10-23 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| MX393138B (es) | 2011-04-25 | 2025-03-24 | Sanofi Sa | Compuestos de microarn y metodos para modular la actividad de mir-21. |
| EP4008786A3 (en) * | 2011-09-06 | 2022-08-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | The mirna-212/132 family as a therapeutic target |
| EP2763703B1 (en) | 2011-10-06 | 2018-02-14 | Miragen Therapeutics, Inc. | Control of whole body energy homeostasis by microrna regulation |
| EP2592145A1 (en) * | 2011-11-11 | 2013-05-15 | Medizinische Hochschule Hannover | Medicament for the treatment of cardiac disease |
| BR112014012288A2 (pt) * | 2011-11-22 | 2017-05-23 | Intermune Inc | métodos para diagnosticar e tratar fibrose pulmonar idiopática |
| EP2790735A4 (en) * | 2011-12-13 | 2015-12-09 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS |
| US9193971B2 (en) | 2012-04-10 | 2015-11-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for the treatment of nonalcoholic steatohepatitis |
| MY173600A (en) | 2012-04-25 | 2020-02-08 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| CA2782942C (en) | 2012-07-12 | 2019-08-27 | Canadian Blood Services | Method for inducing immune tolerance using polymer-modified antigenic leukocytes |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| EP3019176B1 (en) | 2013-07-12 | 2020-05-06 | Canadian Blood Services | Use of acellular pro-inflammatory compositions and process for making same |
| WO2015061536A1 (en) | 2013-10-25 | 2015-04-30 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| EP3079727A1 (en) * | 2013-12-12 | 2016-10-19 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322 |
| US10561685B2 (en) | 2014-07-10 | 2020-02-18 | Canadian Bllood Services | Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system |
| CN107108685B (zh) * | 2014-09-08 | 2020-10-20 | 米拉根医疗股份有限公司 | miR-29模拟物及其用途 |
| HK1249108A1 (zh) | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| CN106924757B (zh) * | 2015-12-31 | 2020-07-24 | 中国科学院遗传与发育生物学研究所 | miR-449c-5p及其拟似物在制备治疗和预防心脏瓣膜疾病产品中的应用 |
| CN107034216A (zh) * | 2016-02-04 | 2017-08-11 | 中国科学技术大学 | miRancer分子的设计与应用 |
| KR101835018B1 (ko) | 2016-03-03 | 2018-03-06 | 고려대학교 산학협력단 | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 |
| US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| WO2019050071A1 (ko) | 2017-09-08 | 2019-03-14 | 고려대학교 산학협력단 | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 |
| CN107858419A (zh) * | 2017-11-10 | 2018-03-30 | 青岛大学 | miRNA的应用、应用其的产品及检测方法 |
| MY199134A (en) | 2018-05-25 | 2023-10-17 | Bioneer Corp | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis related diseases and respiratory diseases, comprising same |
| CN109498642A (zh) * | 2018-12-21 | 2019-03-22 | 复旦大学附属中山医院 | 一种柯萨奇b3病毒感染导致的心脏微血管病变的靶向治疗药物 |
| MX2022012544A (es) | 2020-04-09 | 2022-11-07 | Univ Muenchen Tech | Liberacion dirigida de un inhibidor de mir-21 a macrofagos para el tratamiento de la fibrosis pulmonar. |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| WO2022026851A1 (en) * | 2020-07-31 | 2022-02-03 | The Scripps Research Institute | Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna |
| US20240141340A1 (en) * | 2021-03-05 | 2024-05-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
| KR102549208B1 (ko) * | 2021-04-08 | 2023-06-30 | 연세대학교 산학협력단 | 심혈관 질환과 관련된 LncRNA 및 이의 용도 |
| CN118667869B (zh) * | 2024-07-10 | 2025-06-27 | 中国水稻研究所 | 水稻氮素利用基因nu4在调控水稻生长中的应用 |
| EP4741501A1 (en) | 2024-11-11 | 2026-05-13 | RNATICS GmbH | Dosing of oligonucleotide drugs targeting mir-21 for inhalation |
| CN122251428A (zh) * | 2026-05-27 | 2026-06-23 | 天津医科大学第二医院 | 二甲双胍联合miR-21激动剂在治疗糖尿病性骨质疏松中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050115231A (ko) * | 2003-02-10 | 2005-12-07 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 포유동물 세포의 조절 |
| AU2004221760B2 (en) * | 2003-03-21 | 2010-03-18 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
| JP2007511487A (ja) * | 2003-11-17 | 2007-05-10 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| CA2566519C (en) | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| EP1827458A4 (en) * | 2004-11-09 | 2010-02-17 | Baylor College Medicine | SELECTIVE INHIBITION OF ROCK 1 IN HEART THERAPY |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| CA3042781C (en) * | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| JP2010505427A (ja) | 2006-10-09 | 2010-02-25 | ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ | 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ） |
| EP2104735A2 (en) * | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
-
2008
- 2008-02-27 EP EP20080003570 patent/EP2096171A1/en not_active Withdrawn
-
2009
- 2009-02-19 WO PCT/EP2009/051986 patent/WO2009106477A1/en not_active Ceased
- 2009-02-26 PT PT97140792T patent/PT2260101E/pt unknown
- 2009-02-26 EP EP20130160931 patent/EP2628800A1/en not_active Withdrawn
- 2009-02-26 KR KR1020107021182A patent/KR101697482B1/ko not_active Expired - Fee Related
- 2009-02-26 MY MYPI2010004041A patent/MY159454A/en unknown
- 2009-02-26 MX MX2010009346A patent/MX2010009346A/es active IP Right Grant
- 2009-02-26 HR HRP20130766AT patent/HRP20130766T1/hr unknown
- 2009-02-26 EP EP09714079.2A patent/EP2260101B1/en active Active
- 2009-02-26 WO PCT/EP2009/001590 patent/WO2009106367A1/en not_active Ceased
- 2009-02-26 DK DK09714079.2T patent/DK2260101T3/da active
- 2009-02-26 BR BRPI0907565-8A patent/BRPI0907565B1/pt not_active IP Right Cessation
- 2009-02-26 CA CA3123067A patent/CA3123067A1/en not_active Abandoned
- 2009-02-26 UA UAA201011410A patent/UA100727C2/ru unknown
- 2009-02-26 AU AU2009218704A patent/AU2009218704C1/en not_active Ceased
- 2009-02-26 NZ NZ588185A patent/NZ588185A/xx not_active IP Right Cessation
- 2009-02-26 SI SI200930690T patent/SI2260101T1/sl unknown
- 2009-02-26 PL PL09714079T patent/PL2260101T3/pl unknown
- 2009-02-26 ME MEP-2013-93A patent/ME01600B/me unknown
- 2009-02-26 EA EA201070992A patent/EA020335B1/ru unknown
- 2009-02-26 CA CA2716643A patent/CA2716643C/en active Active
- 2009-02-26 JP JP2010548040A patent/JP6033527B2/ja not_active Expired - Fee Related
- 2009-02-26 US US12/919,592 patent/US8236777B2/en active Active
- 2009-02-26 ES ES09714079.2T patent/ES2436885T3/es active Active
- 2009-02-26 MX MX2011012838A patent/MX336299B/es unknown
- 2009-02-26 CN CN200980115916.9A patent/CN102027113B/zh not_active Expired - Fee Related
-
2010
- 2010-08-19 IL IL207704A patent/IL207704A/en active IP Right Grant
-
2012
- 2012-06-28 US US13/535,652 patent/US8592389B2/en not_active Expired - Fee Related
-
2013
- 2013-08-13 CY CY20131100690T patent/CY1114426T1/el unknown
- 2013-10-23 US US14/061,350 patent/US9220722B2/en active Active
-
2014
- 2014-12-04 JP JP2014246185A patent/JP2015107971A/ja active Pending
-
2015
- 2015-11-20 US US14/947,291 patent/US9663788B2/en active Active
-
2017
- 2017-04-19 US US15/491,633 patent/US10028974B2/en active Active
-
2018
- 2018-06-22 US US16/015,495 patent/US10434117B2/en active Active
-
2019
- 2019-08-16 US US16/542,985 patent/US20200069720A1/en not_active Abandoned
-
2020
- 2020-09-01 US US17/008,782 patent/US20210113603A1/en not_active Abandoned
-
2022
- 2022-06-22 US US17/846,518 patent/US20230028937A1/en not_active Abandoned
-
2023
- 2023-11-21 US US18/515,531 patent/US20240189339A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201070992A1 (ru) | МИКРО-РНК (miРНК) И МИШЕНИ СИГНАЛЬНОГО ПУТИ ДЛЯ ДИАГНОСТИЧЕСКИХ И ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ | |
| JOP20210207A1 (ar) | مركبات ترابطية مستهدفة | |
| WO2008043521A3 (de) | Microrna (mirna) zur diagnose und therapie von herzerkrankungen | |
| EA201892285A1 (ru) | Нуклеотиды, модифицированные циклофосфонатом по положению 5' | |
| MX2023006334A (es) | Ligandos dirigidos para compuestos terapeuticos. | |
| EA202191630A1 (ru) | ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| Tu et al. | MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention | |
| CY1120690T1 (el) | Κρυσταλλικη μορφη βενζυλοβενζολικου αναστολεα τουsglt2 | |
| CY1118821T1 (el) | Γελες με βαση υαλουρονικο οξυ οι οποιες περιλαμβανουν αναισθητικους παραγοντες | |
| ATE516353T1 (de) | Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs | |
| WO2008073922A3 (en) | Functions and targets of let-7 micro rnas | |
| Yang et al. | The role of miR-100-mediated Notch pathway in apoptosis of gastric tumor cells | |
| EA201391492A1 (ru) | Соединения на основе микрорнк и способы модулирования активности mir-21 | |
| EP3970720A1 (en) | Compositions and methods for treating pulmonary vascular disease | |
| JP2020511116A (ja) | 体細胞を誘導血管性細胞にリプログラミングするための組成物および方法 | |
| RU2013102545A (ru) | Связывающая vegfa си-рнк и способы лечения in vivo | |
| WO2010003420A2 (en) | Treatment of psoriasis and related diseases by mirna modulation | |
| Xu et al. | Changes in microRNAs expression are involved in age-related atrial structural remodeling and atrial fibrillation | |
| Latronico et al. | Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment | |
| BR112018010736A2 (pt) | oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos | |
| CY1114423T1 (el) | Νεο παραγωγο πυριδινης και παραγωγο πυριμιδινης (3) | |
| WO2010075255A3 (en) | Methods for treating or preventing cancer and neurodegenerative diseases | |
| UY29640A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmacéuticos. | |
| AR084332A1 (es) | miRNA EN ARTROPATIA | |
| Cho et al. | miR-181a post-transcriptionally targets GRK2 to limit maladaptive signaling in cardiomyocytes |